Clinical Effect of Bifidobacterium Quadruple Viable Bacteria Tablet Combined with Mesalazine Enteric-Coated Tablet in Maintenance Treatment of Ulcerative Colitis
Objective To investigate the effect of Bifidobacterium Quadruple Viable Bacteria Tablet com-bined with Mesalazine Enteric-Coated Tablet in the maintenance treatment of ulcerative colitis(UC).Methods A total of 68 patients with UC in remission from January 2021 to January 2023 were prospec-tively selected as research objects,and randomly divided into the study group and the control group,34 ca-ses in each group.The control group was treated with oral Mesalazine Enteric-Coated Tablet,and the stud-y group was treated with oral Bifidobacterium Quadruple Viable Bacteria Tablet on the basis of the control group,for 6 consecutive months.The recurrence of the two groups during treatment,mucosal Baron score under colonoscopy,Geboes index,fecal calvetin(FC)level,inflammatory factor levels including hyper-sensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)and interleukin-8(IL-8),quality of life(IBDQ scale),and the occurrence of adverse reactions during treatment were compared before and after treatment.Results The recurrence rate of the study group was lower than that of the control group,and the first recurrence time was longer than that of the control group(P＜0.05).After 6 months of treatment,mucosal Baron score under colonoscopy,Geboes index and FC level in both groups were sig-nificantly lower than before treatment(P＜0.05).After 6 months of treatment,mucosal Baron score un-der colonoscopy,Geboes index and FC level in the study group were lower than those in the control group(P＜0.05).The levels of hs-CRP,TNF-α and IL-8 in both groups after 3 months and 6 months of treat-ment were significantly reduced compared with those before treatment,and all indexes after 6 months of treatment were lower than those after 3 months of treatment(P＜0.05).Between groups,the levels of hs-CRP,TNF-α and IL-8 were lower in the study group after 3 months and 6 months of treatment(P＜0.05).After 6 months of treatment,IBDQ scale scores and total scores in both groups were higher than before treatment(P＜0.05).After 6 months of treatment,IBDQ scores and total scores in the study group were higher than those in the control group(P＜0.05).The total incidence of adverse reactions in the study group was lower than that in the control group(P＜0.05).Conclusion Bifidobacterium Quadruple Viable Bacteria Tablet combined with Mesalazine Enteric-Coated Tablet has a good effect in ma-intenance treatment of UC patients,which can effectively alleviate intestinal mucosal status,reduce inflam-mation,reduce adverse reactions,and improve the quality of life of patients.
NETL
NSTL
万方数据
